Technical Analysis for ANRO - Alto Neuroscience, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 1.34% | |
| Inside Day | Range Contraction | 1.34% | |
| Fell Below 20 DMA | Bearish | 6.60% | |
| Fell Below 50 DMA | Bearish | 6.60% | |
| MACD Bearish Centerline Cross | Bearish | 6.60% | |
| 180 Bearish Setup | Bearish Swing Setup | 6.60% | |
| Gapped Down | Weakness | 6.60% | |
| Crossed Above 50 DMA | Bullish | -1.43% | |
| MACD Bullish Centerline Cross | Bullish | -1.43% | |
| 50 DMA Resistance | Bearish | 3.46% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | 9 minutes ago |
| Rose Above 50 DMA | 9 minutes ago |
| Up 1% | 9 minutes ago |
| Up 5% | about 19 hours ago |
| Possible NR7 | about 20 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/21/2024
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto's Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Neuroscience Schizophrenia Biomarkers Depression Neurophysiology Post Traumatic Stress Disorder Electroencephalography Neurocognition Ptsd
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Neuroscience Schizophrenia Biomarkers Depression Neurophysiology Post Traumatic Stress Disorder Electroencephalography Neurocognition Ptsd
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 24.0 |
| 52 Week Low | 12.7798 |
| Average Volume | 171,915 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 14.69 |
| 20-Day Moving Average | 14.28 |
| 10-Day Moving Average | 14.78 |
| Average True Range | 1.04 |
| RSI (14) | 50.00 |
| ADX | 16.68 |
| +DI | 19.96 |
| -DI | 16.69 |
| Chandelier Exit (Long, 3 ATRs) | 13.41 |
| Chandelier Exit (Short, 3 ATRs) | 15.91 |
| Upper Bollinger Bands | 15.79 |
| Lower Bollinger Band | 12.77 |
| Percent B (%b) | 0.61 |
| BandWidth | 21.15 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.07 |
| MACD Histogram | 0.0408 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 15.95 | ||||
| Resistance 3 (R3) | 15.82 | 15.24 | 15.73 | ||
| Resistance 2 (R2) | 15.24 | 14.89 | 15.30 | 15.65 | |
| Resistance 1 (R1) | 14.92 | 14.68 | 15.08 | 15.05 | 15.57 |
| Pivot Point | 14.34 | 14.34 | 14.42 | 14.40 | 14.34 |
| Support 1 (S1) | 14.02 | 13.99 | 14.18 | 14.15 | 13.63 |
| Support 2 (S2) | 13.44 | 13.78 | 13.50 | 13.55 | |
| Support 3 (S3) | 13.12 | 13.44 | 13.48 | ||
| Support 4 (S4) | 13.25 |
